2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 432

Monitoring Hepatitis B Screening Compliance in Patients with Rheumatoid Arthritis (RA) Receiving Anti-TNF Therapy
Abstract Number: 433

The Prevalence of Latent Tuberculosis and Hepatitis B Found after Systematic Screening of Patients Starting with Biological Therapy in a Low-Endemic Area
Abstract Number: 434

Nurse Scheduled Telephone Visit: The Right Rheumatology Care for the Right Patient at the Right Time
Abstract Number: 435

It Takes Two, an Interdisciplinary Approach to Increasing Hydroxychloroquine Screening Adherence
Abstract Number: 436

Are Providers Recommending Appropriate Screening for Hydroxychloroquine-Induced Retinal Toxicity to Their Patients?
Abstract Number: 437

Incidence of Gastrointestinal Events and Physician Compliance of Co-Prescribing Proton Pump Inhibitors in Chronic NSAID Users with Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis
Abstract Number: 438

Glucocorticoid Adverse Effects – the Patient Perspective
Abstract Number: 439

Temple University Hospital Rheumatology Narcotic Contract
Abstract Number: 440

the Majority of Biologic Injectors Are Stored Under Suboptimal Conditions at Home
Abstract Number: 441

Improving Care and Avoiding Errors. Can Our Patients Recall Their Medications and Create an Accurate Medication List?
Abstract Number: 442

Comparison of Adherence and Dosing Interval of Subcutaneous Anti-TNF Biologics in Inflammatory Arthritis from a Canadian Administrative Database.
Abstract Number: 443

Repetitive Requisition of Antinuclear Antibody Testing (ANA) in Outpatient Multispecialty Clinics in Patients with a Known Positive ANA
Abstract Number: 444

Improvement in Knee Arthrocentesis Via Constant Compression
Abstract Number: 445

Performance of Promis Measures in a Multi-Ethnic Population-Based Systemic Lupus Erythematosus (SLE) Cohort
Abstract Number: 446

A Multi-Group Confirmatory Factor Analyses of the Lupuspro Between Southern California and Filipino Samples of Patients with SLE

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].